These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10741275)
1. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Udom DI; Vigushin DM; Linardou H; Graham H; Palmieri C; Coombes RC Eur J Cancer; 2000 Jan; 36(2):177-82. PubMed ID: 10741275 [TBL] [Abstract][Full Text] [Related]
2. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331 [TBL] [Abstract][Full Text] [Related]
3. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Zelek L; Barthier S; Riofrio M; Fizazi K; Rixe O; Delord JP; Le Cesne A; Spielmann M Cancer; 2001 Nov; 92(9):2267-72. PubMed ID: 11745280 [TBL] [Abstract][Full Text] [Related]
4. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543 [TBL] [Abstract][Full Text] [Related]
5. Weekly schedule of vinorelbine in pretreated breast cancer patients. Nisticò C; Garufi C; Milella M; Vaccaro A; D'Ottavio AM; Fabi A; Pace A; Bove L; Tropea F; Marsella A; Izzo F; D'Attino RM; Ferraresi V; De Marco S; Terzoli E Breast Cancer Res Treat; 2000 Feb; 59(3):223-9. PubMed ID: 10832592 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155 [TBL] [Abstract][Full Text] [Related]
8. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Kosmas C; Agelaki S; Giannakakis T; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V Oncology; 2002; 62(2):103-9. PubMed ID: 11914594 [TBL] [Abstract][Full Text] [Related]
12. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Vogel C; O'Rourke M; Winer E; Hochster H; Chang A; Adamkiewicz B; White R; McGuirt C Ann Oncol; 1999 Apr; 10(4):397-402. PubMed ID: 10370781 [TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Baweja M; Suman VJ; Fitch TR; Mailliard JA; Bernath A; Rowland KM; Alberts SR; Kaur JS; Perez EA; Ann Oncol; 2006 Apr; 17(4):623-9. PubMed ID: 16520332 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795 [TBL] [Abstract][Full Text] [Related]
16. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Pieńkowski T; Jagiello-Gruszfeld A Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140 [TBL] [Abstract][Full Text] [Related]
17. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study. Cals L; Nouyrigat P; Valenza B; Pedinelli FJ; Juin P Oncology; 2004; 67(3-4):257-61. PubMed ID: 15557787 [TBL] [Abstract][Full Text] [Related]
18. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089 [TBL] [Abstract][Full Text] [Related]
19. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients. Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525 [TBL] [Abstract][Full Text] [Related]
20. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Ibrahim NK; Valero V; Rahman Z; Theriault RL; Walters RS; Buzdar AU; Booser DJ; Holmes FA; Murray JL; Willey J; Bast R; Hortobagyi GN Cancer Invest; 2001; 19(5):459-66. PubMed ID: 11458813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]